Daewoong Pharm develops anticancer drug using XtalPi's AI platform
Daewoong Pharm develops anticancer drug using XtalPi's AI platform
  • Kim Min-jee
  • 승인 2022.04.13 13:37
  • 댓글 0
이 기사를 공유합니다

Daewoong Pharmaceutical is launching an anticancer drug research and development using an artificial intelligence (AI) platform.

Daewoong Pharmaceutical announced today that it has signed a contract for joint research and development of an anticancer drug using an AI-based drug development platform with XtalPi on March 31.

Through this contract, the two companies will form a new drug development partnership and jointly develop anticancer target drugs based on the principle of synthetic lethality.

XtalPi uses its proprietary drug development cloud computing platform to discover new drug candidates for selected anticancer targets.

After that, Daewoong Pharmaceutical plans to proceed with commercialization such as preclinical and clinical development. The results of the joint research are owned by Daewoong Pharmaceutical.

XtalPi is an AI-based drug R&D company based on quantum physics. Founded in 2014 by quantum physics experts at MIT, it has developed a digital drug discovery and development platform, serving more than 70 pharmaceutical companies worldwide, including 7 of the top 10 pharmaceutical companies.

XtalPi's quantum mechanics-based artificial intelligence drug discovery platform, which will be used for joint research with Daewoong Pharmaceutical, combines machine learning to predict the pharmaceutical properties of a wide range of molecular compounds.

This is expected to enable more efficient discovery of new drug candidates.

“Daewoong Pharmaceutical has high expectations for joint research with XtalPi, which has expertise in medicine and chemistry as well as artificial intelligence technology," said Daewoong Pharmaceutical CEO Jeon Seung-ho. "We will accelerate the development of next-generation anticancer drugs through an AI-based new drug development platform that can overcome the limitations of general drug development time and risks.”

“The artificial intelligence platform enables us to find new and developable lead materials in difficult targets faster," said XtalPi CEO Jian Ma. "We expect that Daewoong Pharmaceutical's R&D capabilities and XtalPi's AI-based platform technology will effectively discover effective and safe drug candidates for clinical trials."


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • ABOUT
  • CONTACT US
  • SIGN UP MEMBERSHIP
  • RSS
  • 2-D 678, National Assembly-daero, 36-gil, Yeongdeungpo-gu, Seoul, Korea (Postal code: 07257)
  • URL: www.koreaittimes.com | Editorial Div: 82-2-578- 0434 / 82-10-2442-9446 | North America Dept: 070-7008-0005 | Email: info@koreaittimes.com
  • Publisher and Editor in Chief: Monica Younsoo Chung | Chief Editorial Writer: Hyoung Joong Kim | Editor: Yeon Jin Jung
  • Juvenile Protection Manager: Choul Woong Yeon
  • Masthead: Korea IT Times. Copyright(C) Korea IT Times, All rights reserved.
ND소프트